MarketCap
Ironwood Pharmaceuticals IRWD
$ 4.82
3.88%
Facebook
X
Telegram
Ironwood Pharmaceuticals ROCE Ratio | IRWD
Annual ROCE Ratio Ironwood Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -37.62 | -30.9 | 273.01 | 38.37 | 38.33 | 228.19 | 32.35 | -48.0 | -20.08 | -6.73 | -15.56 | -62.05 | -105.92 | -41.59 | -45.98 | -38.09 | 20.38 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 273.01 | -105.92 | 10.48 |
Quarterly ROCE Ratio Ironwood Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.82 | -26.16 | -72.3 | -30.17 | -45.02 | -24.68 | -17.73 | -29.78 | -30.19 | -34.24 | 285.87 | 297.7 | 320.14 | 342.88 | 41.7 | 33.2 | 44.44 | 45.57 | 76.33 | 65.16 | 147.19 | 908.58 | 807.09 | 747.41 | 612.19 | -203.49 | -124.55 | -98.93 | 28.54 | 104.99 | 313.52 | 306.38 | 1167.33 | 1203.6 | 328.09 | -4.58 | -907.93 | -1041.44 | -202.28 | -68.3 | -95.83 | -83.38 | -101.6 | -98.65 | -136.06 | -142.5 | -151.42 | -133.73 | -218.6 | -251.78 | -255.87 | -384.17 | -228.85 | -190.04 | -171.83 | -20.04 | -39.71 | -90.01 | -78.55 | -53.81 | -19.68 | -17.25 | -16.88 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1203.6 | -1041.44 | 36.9 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
UroGen Pharma Ltd.
URGN
|
-81.06 | $ 25.32 | -3.78 % | $ 1.22 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
10.83 | $ 13.91 | 1.9 % | $ 1.24 B |  USA |
 |
ARCA biopharma
ABIO
|
-25.79 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-17.34 | - | 4.01 % | $ 150 M |  Canada |
 |
ADiTx Therapeutics
ADTX
|
-348.87 | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
-76.42 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.14 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
-299.27 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-41.2 | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
14.97 | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-229.05 | - | - | $ 269 M | USA |
 |
AVROBIO
AVRO
|
-33.43 | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
16.47 | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
99.68 | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
-79.52 | $ 0.39 | 9.06 % | $ 28.6 K | USA |
 |
Bio-Path Holdings
BPTH
|
-7787.01 | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-127.7 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
18.82 | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-122.58 | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-123.17 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-123.17 | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
-155.27 | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
50.04 | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
96.98 | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
-19.96 | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
-4.54 | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-113.79 | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
152.79 | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
33.52 | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
11.96 | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
-119.97 | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
-87.69 | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
-75.18 | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
-235.71 | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
-63.97 | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
-44.94 | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
63.19 | $ 10.15 | -6.8 % | $ 1.64 B | USA |
 |
Hepion Pharmaceuticals
HEPA
|
-156.09 | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
-200.97 | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
-26.04 | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-104.22 | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
-25.64 | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
-84.35 | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
-52.85 | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
-35.57 | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
-111.88 | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
-257.04 | - | 0.43 % | $ 12 M | USA |